NCT00759720View on ClinicalTrials.gov

Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

PHASE3TerminatedINTERVENTIONAL
Enrollment

447

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Diabetes Mellitus
Interventions
DRUG

TAK-559 and glyburide

TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.

DRUG

TAK-559 and glyburide

TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.

DRUG

Glyburide

TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00759720 - Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus. | Biotech Hunter | Biotech Hunter